

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replica⦠read more
Healthcare
Biotechnology
19 years
USD
Exclusive to Premium users
$4.36
Price+0.46%
$0.02
$861.264m
Small
5.3x
Premium
Premium
+94.8%
EBITDA Margin+94.7%
Net Profit Margin-4.5%
Free Cash Flow Margin+94.8%
EBITDA Margin+94.7%
Net Profit Margin-4.5%
Free Cash Flow Margin$191.445m
+1259.4%
1y CAGR+440.5%
3y CAGR+317.0%
5y CAGR$160.720m
+579.8%
1y CAGR+212.0%
3y CAGR+157.7%
5y CAGR$0.82
+582.4%
1y CAGR+217.1%
3y CAGR+163.9%
5y CAGR$260.177m
$277.164m
Assets$16.987m
Liabilities$3.909m
Debt1.4%
-
Debt to EBITDA-$34.356m
+13.3%
1y CAGR+25.9%
3y CAGR-16.2%
5y CAGR